7 October 2016 - Mylan, the maker of the allergy treatment EpiPen, said Friday that it had reached a $465 million settlement with the Justice Department and other government agencies over questions on whether the company had overcharged Medicaid for the treatment by improperly classifying it as a generic medicine.

The federal government said this week that Mylan had been told multiple times that it was wrongly classifying the EpiPen, which led the Medicaid and Medicare programs to overpay for the product. Although it has not been disclosed how much it had overpaid, officials said spending on the EpiPen totaled nearly $1.3 billion from 2011 to 2015.

Mylan has been under intense scrutiny since the summer for raising the price of EpiPen to more than $600 for a pack of two from about $100 since it bought the product in 2007.

Read New York Times article